2 active not recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Miransertib: new trials by email Literature Review of Miransertib trials Research Report on Miransertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-7075 (Miransertib) in Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 2 | Active not recruiting | National Human Genome Research Institute (NHGRI) | 38 | 2022-05-20 | 2026-07-17 |
| A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2021-11-02 | 2025-02-07 |
| Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | Phase 1 / Phase 2 | Terminated | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 50 | 2017-05-16 | 2023-04-13 |
Congenital Abnormalities (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Proteus Infections (1) · Proteus Syndrome (1)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Merck Sharp & Dohme LLC (1) · National Human Genome Research Institute (NHGRI) (1)
United States (3) · Australia (2) · Italy (2) · Brazil (1) · Spain (1) · United Kingdom (1)
PMID 33639990, PMID 40713644, PMID 42224880
2016 (1)